Does serum calcium level play a practical role in calciphylaxis in hemodialysis patients?

Lijing ZhangDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information

Yu ZhaoDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information

Zhong GuoDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information

Jianxiu MaDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information

Yanqing MaDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information

Zhanli YangDepartment of Medicine, Northwest Minzu University, Lanzhou, PR ChinaCorrespondence[email protected]
View further author information

References

Liu Y, Zhang X, Xie X, et al. Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study. Ren Fail. 2021; 43(1):406–416.
PubMed Web of Science ®Google Scholar
Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a natched case-control study. Am J Nephrol. 2013; 37(4):325–332.
PubMed Web of Science ®Google Scholar
Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429.
PubMed Web of Science ®Google Scholar
Gaisne R, Péré M, Menoyo V, et al. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a casecontrol study. BMC Nephrol. 2020; 21(1):63.
PubMed Web of Science ®Google Scholar
Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580–1584.
PubMed Web of Science ®Google Scholar